197(top 1%)
papers
8.5K(top 1%)
citations
44(top 1%)
h-index
89(top 1%)
g-index
206
all documents
8.9K
doc citations
2.0K
citing journals
127
times ranked

Top Articles

#TitleJournalYearCitations
1Cognitive Function in Breast Cancer Patients Receiving Adjuvant ChemotherapyJournal of Clinical Oncology2000511
2Evolution of human BCR–ABL1 lymphoblastic leukaemia-initiating cellsNature2011421
3Cognitive Impairment Associated With Chemotherapy for Cancer: Report of a WorkshopJournal of Clinical Oncology2004400
4Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myelomaLeukemia2009350
5Targeting the protein kinase C family: are we there yet?Nature Reviews Cancer2007343
6Novel patterns of response under immunotherapyAnnals of Oncology2019343
7Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibLeukemia2008341
8The EGFRvIII variant in glioblastoma multiformeJournal of Clinical Neuroscience2009325
9Male breast carcinomaJournal of Clinical Neuroscience1999282
10Potential Drug Interactions and Duplicate Prescriptions Among Cancer PatientsJournal of the National Cancer Institute2007279
11Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant ChemotherapyJournal of Clinical Oncology2013270
12Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North AmericaCancer2010240
13K-ras Mutations in Non-Small-Cell Lung Carcinoma: A ReviewClinical Lung Cancer2006212
14Molecular predictive and prognostic markers in non-small-cell lung cancerLancet Oncology, The2009194
15Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphomaAnnals of Oncology2008165
16Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitorsAnnals of Oncology2009147
17Epoetin Alfa Therapy Increases Hemoglobin Levels and Improves Quality of Life in Patients With Cancer-Related Anemia Who Are Not Receiving Chemotherapy and Patients With Anemia Who Are Receiving ChemotherapyJournal of Clinical Oncology2001143
18Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancerCancer2010143
19A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patientsAnnals of Oncology2007139
20Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemiaBlood2020127
21Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumorsAnnals of Oncology2012125
22Conventional cancer therapy: promise broken or promise delayed?Lancet, The1998117
23HIGH RISK OF VASCULAR EVENTS IN PATIENTS WITH UROTHELIAL TRANSITIONAL CELL CARCINOMA TREATED WITH CISPLATIN BASED CHEMOTHERAPYJournal of Urology1998106
24Lung cancer screening using low-dose computed tomography in at-risk individuals: The Toronto experienceLung Cancer2010106
25The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance])Blood2015104
26Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple MyelomaJournal of Clinical Oncology2008100
27Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myelomaCancer Chemotherapy and Pharmacology201197
28Is the international staging system superior to the Durie–Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplantLeukemia200981
29Impact and Feasibility of a Comprehensive Geriatric Assessment in the Oncology SettingAmerican Journal of Clinical Oncology: Cancer Clinical Trials201277
30Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumorsAnnals of Oncology201677
31Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted TherapyUrology201075
32Immunotherapy for Non-small Cell Lung Cancer: Novel Approaches to Improve Patient OutcomeJournal of Thoracic Oncology201170
33Consistency in the Analysis and Reporting of Primary End Points in Oncology Randomized Controlled Trials From Registration to Publication: A Systematic ReviewJournal of Clinical Oncology201269
34Delayed emesis: moderately emetogenic chemotherapySupportive Care in Cancer200564
35Comorbidity, age and overall survival in patients with advanced pancreatic cancer – Results from NCIC CTG PA.3: A phase III trial of gemcitabine plus erlotinib or placeboEuropean Journal of Cancer201263
36Myeloperoxidase and superoxide dismutase polymorphisms are associated with an increased risk of developing pancreatic adenocarcinomaCancer200858
37Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cellsLeukemia Research201055
38Treatment of the Elderly When Cure is the Goal: The Influence of Age on Treatment Selection and Efficacy for Stage III Non-small Cell Lung CancerJournal of Thoracic Oncology201155
39Bereavement Practices of Physicians in Oncology and Palliative CareArchives of Internal Medicine200951
40Impact of Patient Age and Comorbidity on Surgeon Versus Oncologist Preferences for Adjuvant Chemotherapy for Stage III Colon CancerJournal of the American College of Surgeons200950
41A Systematic Review on Drug Interactions in OncologyCancer Investigation200649
42Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysisBritish Journal of Cancer201349
43Utilization of prophylactic cranial irradiation in patients with limited stage small cell lung carcinomaCancer201048
44Initial Biopsy Gleason Score as a Predictive Marker for Survival Benefit in Patients with Castration-resistant Prostate Cancer Treated with Docetaxel: Data from the TAX327 StudyEuropean Urology201448
45Therapy‐related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosisCancer201247
46The World Ovarian Cancer Coalition Every Woman Study: identifying challenges and opportunities to improve survival and quality of lifeInternational Journal of Gynecological Cancer202147
47Evidence-based recommendations for the use of antiemetics in radiotherapyRadiotherapy and Oncology200546
48Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States11Funding source: The US Office of Management and Budget (0925-0046).Urologic Oncology: Seminars and Original Investigations201446
49D(T)PACE as salvage therapy for aggressive or refractory multiple myelomaBritish Journal of Haematology201345
50Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelinesSupportive Care in Cancer200544